Regulators added two oral antibiotics to the gonorrhea treatment toolbox: Innoviva’s zoliflodacin (Nuzolvence) and GSK’s gepotidacin (Blujepa) secured approvals/label expansions as supplemental therapies for uncomplicated gonorrhea. Both drugs earned expedited regulatory designations during development. Sponsors say the oral options expand alternatives amid rising antimicrobial resistance and will be integrated into treatment guidelines. GSK additionally announced a label expansion to cover urogenital gonorrhea in adolescents and adults. Clinicians welcomed the approvals as meaningful for stewardship and patient access, while infectious‑disease experts stressed surveillance and stewardship to limit emergence of new resistance.